tradingkey.logo

Northstrive Biosciences Announces Positive FDA Response Supporting A Submission Of IND For A Phase 2 Clinical Trial For EL-22 In Combination With GLP-1 Receptor Agonist For Obesity Treatment

ReutersApr 24, 2025 12:18 PM

- PMGC Holdings Inc ELAB.O:

  • NORTHSTRIVE BIOSCIENCES ANNOUNCES POSITIVE FDA RESPONSE SUPPORTING A SUBMISSION OF IND FOR A PHASE 2 CLINICAL TRIAL FOR EL-22 IN COMBINATION WITH GLP-1 RECEPTOR AGONIST FOR OBESITY TREATMENT

  • PMGC HOLDINGS INC - NORTHSTRIVE TO FILE IND APPLICATION IN 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI